Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
BCW Member Greyston, the creator of the no-judgement hiring process known as Open Hiring®, celebrated its new offices with ribbon-cutting ceremony on Wednesday joined by a host of dignitaries who praised the organization for eliminating barriers to employment for thousands. Dignitaries including New York State Majority Leader Andrea Stewart-Cousins, Yonkers Mayor Mike Spano, Westchester County […]
Congratulations to BCW Member MacQuesten Development LLC on the groundbreaking for The St. Clair, a $60 million development featuring 78 affordable apartments and commercial space in downtown Yonkers. Located at 34 Main Street, the development is a partnership with the State of New York’s Homes and Community Renewal Program, Westchester County and the City of […]
The BCW has joined with business groups throughout the state in the first of several state-wide information campaigns launched by the Business Council of New York State to educate New York voters on the impacts of significant legislation approved by state lawmakers. The first campaign will focus on the importance of a credible, reliable and […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.